No Data
No Data
Xiang Xue Pharmaceutical (300147.SZ): TCR-T and CAR-T are both adjuvant immune cell treatments
Gelonghui, May 11 | Xiangxue Pharmaceutical (300147.SZ) said on the interactive platform that TCR-T and CAR-T are both secondary immune cell treatments, that is, immune cells are isolated from cancer patients, genetically modified and amplified in vitro, and then transported back to the patient's body, but their mechanisms for recognizing antigens are quite different. CAR-T cells use antibody fragments that bind to specific antigens on the surface of cancer cells. TCR-T cells can recognize tumor-specific antigens from the surface of cell membranes or from within cells, and can target most tumor-specific antigens, especially those within tumor cells. So TC
Strong Week for Xiangxue PharmaceuticalLtd (SZSE:300147) Shareholders Doesn't Alleviate Pain of Three-year Loss
It is doubtless a positive to see that the Xiangxue Pharmaceutical Co.,Ltd. (SZSE:300147) share price has gained some 38% in the last three months. But that doesn't help the fact that the three yea
Xiangxue Pharmaceutical (300147.SZ) announced first-quarter results, changing profit to loss of 35.66 million yuan
Xiangxue Pharmaceutical (300147.SZ) released its report for the first quarter of 2024. The company's revenue was 5.69...
Xiangxue Pharmaceutical (300147.SZ): The clinical trial of TAEST16001 injection with a new indication was accepted
Gelonghui, Feb. 7, 丨 Xiangxue Pharmaceutical (300147.SZ) announced that recently, Xiangxue Life Science Technology (Guangdong) Co., Ltd. (“Xiangxue Life Science”), a subsidiary of Guangzhou Xiangxue Pharmaceutical Co., Ltd., submitted an application for clinical registration of new indications of TAEST16001 injection to the State Drug Administration and received the “Notice of Acceptance” (acceptance number: CXSL2400103) approved and issued by the China Drug Administration.
Xiangxue Pharmaceutical Co.,Ltd.'s (SZSE:300147) 29% Dip In Price Shows Sentiment Is Matching Revenues
The Xiangxue Pharmaceutical Co.,Ltd. (SZSE:300147) share price has fared very poorly over the last month, falling by a substantial 29%. The drop over the last 30 days has capped off a tough year fo
Xiangxue Pharmaceutical (300147.SZ): Pre-loss of 278 million yuan to 468 million yuan in 2023
Gelonghui, January 30, 丨 Xiangxue Pharmaceutical (300147.SZ) announced its 2023 annual performance forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 277.7 million yuan - 467.7 million yuan, loss of 533.16 million yuan for the same period of the previous year; net profit loss after deducting non-recurring profit and loss of 213.8 million yuan - 403.8 million yuan, loss of 553.11 million yuan for the same period last year; operating income of 2242.7 million yuan - 2324.9 million yuan, and operating income after deduction of 219.72.27 million yuan 2.7 million yuan. In 2023, the company focused on development
No Data